RDX Medical Group (LSE: EDX) is an 8p company with a £31 m market cap and develops and supplies innovative digital diagnostic products and services, and announces the appointment of a new Chairman to join the founder and 32% shareholder, Sir Chris Evans.
The Chairman, Professor Owen, has a proven track record of R&D, Funding and global leadership in GlaxoSmithKline, with a broad knowledge of the Pharma industry and of the finance community. In August 2026, the Company raised £2.7m at 14p to support the expansion of its new employee health screening service, and entered into agreements in principle to provide the service to three significant UK employers. Progress was reported in September with a £1.5m three contract signed with Arnold Clark Group, others should be following. In July. there was the full launch of the Company’s comprehensive bowel cancer biomarker testing service in the UK. The UK cancer diagnostics market is growing rapidly, with a substantial uplift in overall value forecast over the next few years.
The Company was listed in May 2026 at c.11p with a scalable growth strategy and potential to compete in the £10 billion+ clinical diagnostics market in UK and Europe. The Finals to March 2026 reported revenue of £330k and losses of £5.7m.
Comment: The shares are not far from the low, as further funding is likely being anticipated, though good news could come first. Perhaps a speculative trade.